GLP-1s

EUREKA! The Top Endocrine Science of 2025

For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...

Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...

As GLP-1 Prescriptions Soar, Poison Center Study Finds Exposures Are Common But Generally Mild

A new study from a poison control center in Alabama offers a reassuring perspective on the rising number of calls related to popular GLP-1 receptor agonists, such as Ozempic and Wegovy. While exposures to these medications have increased significantly over the past two decades, the research suggests many cases are accidental, associated with mild symptoms,...

GLP-1s Show Promise in Treating Alcohol and Drug Addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society. The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders. “Early...

GLP-1s

Endocrine news on twitter